Across the library, O13 tail, at least three tails and a tertiary amine were associated with potent Factor VII silencing; surface pKa of at least approximately 5.5 was also required for strong activity. These are library-level findings, not a 304O13-only causal experiment.
· PDF pp. 6-7, Fig. 5 and Table 2.sales@dcchemicals.com
304O13
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| 304O13 | 50 | Ionizable lipid |
| Cholesterol | 38.5 | Sterol |
| DSPC | 10.75 | Helper phospholipid |
| mPEG2000-DMG (paper MW 2660) | 0.75 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation calculator unavailable. Calculator is enabled only for the explicitly reported molar formulation; the optimized 0.75 mol% PEG condition leaves 10.75 mol% DSPC by direct subtraction from the paper's 50:38.5:(11.5-X):X expression. No N/P is inferred. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedOptimized 304O13 LNP EC50 0.01 mg/kg siRNA; after one 0.1 mg/kg injection, Factor VII remained suppressed for 18 days.Optimized PEG condition, anti-FVII siRNA IV · Non-targeting siRNA controls and non-optimized PEG conditionsPDF p. 4, Fig. 3c-d.
Literature-reportedHigh CD45 silencing in CD11b+ monocyte/macrophage populations from peritoneal cavity and CD11c+ dendritic cells from spleen; peritoneal silencing up to approximately 90% and splenic silencing up to approximately 40% in the plotted results.304O13 CD45-siRNA LNP, 3 days post IV injection · Non-targeting siRNA LNPs and other lipidoidsPDF p. 4, Fig. 3e-f.
Literature-reportedAt 1 h, 304O13 Cy5.5-siRNA signal was primarily liver (42%) and spleen (24%), with 18% in kidneys; naked siRNA was 14% liver, 1% spleen and 71% kidneys.Cy5.5-siRNA, 1 mg/kg IV · Naked siRNAPDF p. 5, Fig. 4a-b.
Additional reported findings
304O13 was hydrolyzed under acidic and basic conditions in the Methods; this demonstrates chemical degradability under the tested conditions and is not an in-vivo clearance half-life.
· PDF p. 8, Lipidoid hydrolysis Methods.Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetWhitehead KA, Dorkin JR, Vegas AJ, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nature Communications. 2014;5:4277. DOI: 10.1038/ncomms5277
All quantitative claims apply to the cited 304O13 LNP formulations and mouse assays, not to the neat lipid alone.
All quantitative claims apply to the cited 304O13 LNP formulations and mouse assays, not to the neat lipid alone.